Search
Now showing items 1-1 of 1
Use Of Second Generation Tyrosine Kinase Inhibitors For Second-Line Treatment Of Chronic Myeloid Leukemia After Imatinib Failure
(Akad Doktorlar Yayınevi, 2011)
Invention of imatinib was a great step for much more successful clinical management of chronic myeloid leukemia (CML). Now, two other tyrosine kinase inhibitors (TKIs) are available both for first-line and later treatments ...